Takeda Adds Theravance GI Candidate In Deal Flurry
This article was originally published in PharmAsia News
In its third licensing deal this week, Takeda is allying with Theravance for the global development of a gastrointestinal agent that will bolster its core portfolio in this area.
You may also be interested in...
Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines.